Member Info for Icecool

Depends if the price gets suspended or not in the future… 🤣 which I would find hilarious if you were out. 👍

Jesus the desperation on the BB is unbelievable, just because we raised at 50p, was everyone moaning about Dr Smith when we were down at 38p in 2022 then rapidly rose back up to 185 odd, people have short memories. The way people are talking you would have thought the trial has completely failed and we have all lost our cash 🤦‍♂️. As for you Thorn go watch the presentation educate yourself, and as for my average price I have been topping up accumulating at these low levels didn’t think I would ever get the opportunity tbh. Why wouldn’t you institutional investors were oversubscribed at 50p for 26 million odd at a so called 34% discount. Everyone needs to ask themselves, what has really changed since Nov when we were 160p is it anything material (trial failures), or is folk just got faux outrage at the management team because they decided to raise at a shock discount and sentiment has been eroded temporarily. The same people giving up hope now calling for change will likely be shouting Avacta praises once the data released for the 2w study mid year. AVA6000 works dox will do what dox does on tumours sensitive to it. People really need to chill or write a letter to the management team. This will recover in time like it did the last time. Have some patience, we are getting to the efficacy studies now which are designed for success. If you are really wanting out go read up on why you invested in the first place then go watch the latest Q&As again and have some bottle. But don’t cry here…..

Wtf are you on about Thorn, my timelines are from the company not made up from thin air I already made an idiot of you earlier for not watching the Q&A session. Get your facts correct please 👍💯.

Please explain what I have said is ramping?

🤣🤣🤣🤣 what is the point of this post. Do you expect people to feel sorry for you?

Thorn totally ignoring value inflection points, like the 2w data readout.🥱👍

Its AIM 21% dilution in the company and nearly a 70% drop in share price is micro BS. My view It’s clearly unsustainable longer term it goes against all logic and is sentiment driven. The macro argument is we have exceptional data, fully funded going into efficacy trials that should based on the current evidence be a certain formality with the FDA. Yes windy you love to concentrate on the short term chaos and make up hypothetical BS scenarios, as you have a trading agenda. I like to go with the bigger picture of where we are headed longer term based on the science and the fact we are fully funded and in a way better position than Nov, when the price was 160 odd. Don’t care about short term price or chaos, however sentiment can change quickly. 💯

2 years worth of funding and we are going bust 🙄🙄🤣👍 welcome to the BB everyone, Viking R has arrived. 🤦‍♂️

Windy you make it out like we haven’t been at this price before. Micro hypothetical BS as always. The data is fantastic I will continue this conversation once the 2w studies have been announced. If an opportunistic offer does come in nothing I can do about it so not much point moaning or worrying about it in the meantime as it’s highly unlikely based on how pharmaceutical companies buy each other out.

Sorry Thorn because you are not invested did you not get invited to the recent Q&A presentation. Everything is going to plan and they expect results mid year as they can do “parallel studies instead of Sequential” try harder idiot. 🤣🤣

Does that normally happen in pharmaceutical takeover deals, come on windy do some research on how they normally go based on oncology platform technology, before you ask me some hypothetical BS micro question that won’t happen. 🥱🤣👍

We are fully funded already for a genuine inflection point, unfortunately it may seem boring 🥱. However we actually don’t need to raise cash at the moment, best getting more data in first for deals or integrating the full DX business build it up and look at potential spin off when it’s established and cash generating. Loads of future options available, Avacta now have the time to see which are most suitable for stakeholder/shareholder value. The share price and sentiment will turn eventually just need to wait it out or take advantage of this discount.

Back with the Agenda Thorn so transparent…. Timelines slipping? please provide evidence? As I have said many a time, the FDA doesn’t care about share price. 50p or 300p irrelevant, FDA approval will be the official catalyst for Avacta (that’s the investment case), it always has been. We are fully funded, full steam ahead with brilliant data. Don’t mix up short term games based on min dilution, with long term value drivers like FDA approval.

2W trial is full steam ahead, clinical results should be released before the next bond conversion is due, well at least some will be announced imo. Don’t agree with the statement as I have already said (unprofessional and pointless however it does show they know Shareholders are pi55ed off) I do expect some news to get sentiment turning in the near future, even if it is partial results as mentioned earlier.

If HC haven’t forward sold, it might not be in their best interests to sell this cache, they have essentially bagged a 16% discount from the oversubscribed original institutional placing at 50p which was also at a 34% discount, that’s a pretty solid foundation when this short clears and sentiment inevitably turns. 🤔💯

everyone losing their **** for 2.157% dilution. aim is wonderful 🤣🤣🤣. 7% down on 2.157% dilution, logic has certainly left the building. what a bargain sale price top up 🔝 time.

that statement means sweet fa was pointless and unprofessional. logically if they get a huge deal in place the conversion would likely have been paid in cash anyways for future qtrs. if they don’t get a huge deal in the conversion will be paid in shares 🙄. all that statement did was try be diplomatic (agree good word) to the angry shareholder groups that obviously emailed him saying pay this time in cash for sentiment reasons. it has done the opposite folk are even more 😡. it matters not longterm though the fda don’t care about the bond, highly entertaining regardless people losing their ****.

You would be extremely naive to think, Avacta wouldn’t listen to them if they say had decided to forward sell this bunch and would have preferred it in shares this quarter instead of cash. Communication is two ways in business. Of course it’s Avacta’s choice at the end of the day. However a couple of emails back and forth go a long way.

Paying the bond in Cash on this occasion while tempting, would have been a trap imo.

1. It sets an expectation and precedent for future quarters.

2. They have a guaranteed cash runaway to see us through the next 24 months. That’s something you don’t want to be messing with.

3. HC might have asked them for shares on this occasion instead of cash. Communication will be frequent.

4. The reason we raised cash in the first place is to negotiate better deals. See above. 👆

Don’t agree with the note in the RNS about future cash payments being possible, that seems to be buckling under pressure from the shareholder groups that are complaining. Would have preferred they stayed silent, seems a little unprofessional.

Although strategy now seems, get the deals in place then pay whatever left in cash. Seems decent and solid enough for the longterm.

Why are you here???